Literature DB >> 9200467

The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.

P F Robbins1, M El-Gamil, Y F Li, E B Fitzgerald, Y Kawakami, S A Rosenberg.   

Abstract

Recent studies have characterized a number of the Ags that are recognized by melanoma-reactive T cells. Although the majority of tumor Ags appear to represent nonmutated gene products, a variety of epitopes have been shown to arise from either mutated or alternatively processed transcripts. Here, we report that the screening of a cDNA library with a HLA-A24-restricted melanoma-reactive T cell cloid derived from tumor infiltrating lymphocytes resulted in the isolation of a variant of the gp100 gene that had retained the entire fourth intron of this gene, termed gp100-in4. The gp100-in4 transcript could be detected by reverse transcriptase-PCR but could not be detected in Northern blots conducted with melanoma RNA, indicating that it represents a relatively rare transcript. Read-through of this transcript into the region corresponding to the fourth intron gave rise to an additional 35 amino acids not found in the normal gp100 glycoprotein, and a peptide within this region conforming to the HLA-A24 consensus motif (VYFFLPDHL) was shown to be recognized by the T cell cloid. The sequence of the intron was identical with that of a previously isolated genomic gp100 clone, and T cells that recognized the gp100-in4 gene product were found to recognize HLA-A24-matched allogeneic melanoma cell lines and melanocytes, demonstrating that this represents a nonmutated epitope. These results further extend the types of Ags that can be recognized by melanoma-reactive T cells to aberrant transcripts of melanosomal genes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200467

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.

Authors:  Paul F Robbins; Mona El-Gamil; Yong F Li; Gang Zeng; Mark Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

2.  A novel splice variant of Pmel17 expressed by human melanocytes and melanoma cells lacking some of the internal repeats.

Authors:  Sarah E Nichols; Dawn C Harper; Joanne F Berson; Michael S Marks
Journal:  J Invest Dermatol       Date:  2003-10       Impact factor: 8.551

3.  Development of effective immunotherapy for the treatment of patients with cancer.

Authors:  Steven A Rosenberg
Journal:  J Am Coll Surg       Date:  2004-05       Impact factor: 6.113

Review 4.  Database of T cell-defined human tumor antigens: the 2013 update.

Authors:  Nathalie Vigneron; Vincent Stroobant; Benoît J Van den Eynde; Pierre van der Bruggen
Journal:  Cancer Immun       Date:  2013-07-15

Review 5.  Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing.

Authors:  Ken-ichi Hanada; James C Yang
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

6.  Translation of pre-spliced RNAs in the nuclear compartment generates peptides for the MHC class I pathway.

Authors:  Sébastien Apcher; Guy Millot; Chrysoula Daskalogianni; Alexander Scherl; Bénédicte Manoury; Robin Fåhraeus
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 11.205

7.  B16 as a mouse model for human melanoma.

Authors:  W W Overwijk; N P Restifo
Journal:  Curr Protoc Immunol       Date:  2001-05

Review 8.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

9.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

10.  Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.

Authors:  Toshiyuki Baba; Marimo Sato-Matsushita; Akira Kanamoto; Akihiko Itoh; Naoki Oyaizu; Yusuke Inoue; Yutaka Kawakami; Hideaki Tahara
Journal:  J Transl Med       Date:  2010-09-16       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.